Thermo Fisher Scientific(US:TMO) ZACKS·2026-01-26 15:16Core Insights - Thermo Fisher Scientific (TMO) is expected to report quarterly earnings of $6.43 per share, reflecting a 5.4% increase year-over-year, with revenues projected at $11.94 billion, a 4.8% increase compared to the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 0.1%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Revenues- Laboratory Products and Biopharma Services' at $6.15 billion, indicating a year-over-year change of +3.7% [5]. - 'Revenues- Specialty Diagnostics' is expected to reach $1.21 billion, reflecting a +4.8% change year-over-year [5]. - 'Revenues- Life Sciences Solutions' is projected at $2.89 billion, showing an increase of +11.2% from the year-ago quarter [5]. - 'Revenues- Analytical Instruments' is forecasted at $2.19 billion, indicating a slight change of +0.1% from the prior year [6]. Geographic Revenue Insights - North America is expected to generate $6.27 billion in revenues, reflecting a +6.9% year-over-year change [6]. - Asia-Pacific revenues are projected at $2.16 billion, indicating a decline of -1.8% from the previous year [7]. - Revenues from Europe are expected to reach $3.10 billion, showing a +7.2% change year-over-year [8]. - Other regions are estimated to generate $411.17 million, reflecting a -6.3% change from the year-ago quarter [7]. Organic Revenue Growth - The combined assessment suggests that 'Revenue Growth - Organic' will likely reach 2.5%, down from 4.0% in the previous year [8]. Stock Performance - Shares of Thermo Fisher have returned +7.8% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.2% change [8].